Beijing Increasepharm Safety and Efficacy Co., Ltd. was founded in 2017, located in PKUC are Industrial Park, Zhongguancun Life Science Park, covering an area of about 2000 square meters, which including general laboratories, SPF animal rooms and related functional laboratories. The functional laboratory meets the requirements of clinical examination, analysis, histopathology, cell biology, inhalation pharmacology & toxicology and other related index tests. It can meet the pharmacodynamics evaluation of various administration methods such as intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, oral administration, transdermal administration, and pulmonary administration. At present, it has become a national and Zhongguancun high-tech enterprise and undertaken four ‘State Projects for 13th Five-Year Major Essential Drug R&D’.

The company's main business is drug screening, drug efficacy, pharmacokinetics, safety evaluation and other research work. It has two characteristic research platforms, namely,  an aerosol inhalation research platform and a new drug screening research platform. Among them, the TCM aerosol inhalation research platform is the first domestic CRO platform for thedrug efficacy and pharmacokinetic research, which was selected as are presentative project of Zhongguancun Science Park in 2018. The company has solved the problem of multi-component and multi-target research on TCM. Based on satisfying the evaluation of self-developed products, it can provide a series of preclinical research work, which including chemical drugs and TCM screening evaluation, patentability research, action mechanism research, application and registration.